Ceftazidime-Avibactam

Restricted
Restricted

C. diff Risk

High

Oral Bioavailability

NA

Approximate Cost

Spectrum Of Activity

Dosing

May only be ordered by Infectious Disease Physician

2.5 g IV every 8 hr

General Information

Acceptable Uses

  • Reserved for patients with little or no alternative treatment options

  • Management of documented CRE infection

Unacceptable Uses

  • Emperic therpay

  • Management of non-multidrug resistant infections

Common Usage

Patients with documented CRE infection

Drug Monitoring

Lab

  • periodic CBC and CMP

Clinical

  • Hypersensitivity

  • Monitor for neurotoxicity

  • GI effects

Adverse Effects

  • Diarrhea, N/V

  • Pruritis

  • Hypersensitivity reaction

Pharmacology

Antimicrobial class: Cephalosporin combination

Average serum half life: 2.76 hr

Route of Elimination: Primarily urine